[Effect of estradiol dipropionate in various doses on induced uterine sarcomagenesis in mice].
Uterine sarcomas in (CBA X C57B1)F1 mice receiving 1,2-dimethylhydrazine (DMH) developed in 20% of animals. Concomitant administration of estradiol-dipropionate (EP) in doses of 2, 10 and 30 micrograms/mouse significantly increased tumour incidence up to 46.9, 62.5, and 50%, respectively, and shortened their latency: 42.3 weeks in a group receiving DMH alone and 36.7, 38.4 and 30.5 weeks in groups receiving DMH plus 2, 10 or 30 micrograms EP, respectively.